Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

30results about How to "Increased substrate tolerance" patented technology

Preparation method of 2,6-difluorobenzamide by utilizing rhodococcus ruber

The invention relates to a preparation method of 2,6-difluorobenzamide by utilizing rhodococcus ruber. The method comprises the following steps: (1) fermentation and culture of seeds; (2) preparation of rhodococcus ruber suspension fluid; (3) conversion of 2,6-difluorobenzonitrile; (4) preparation of finished products. The invention provides a preparation method of 2,6-difluorobenzamide by utilizing rhodococcus ruber to convert 2,6-difluorobenzonitrile into 2,6-difluorobenzamide. The microorganism conversion method has a very high catalytic efficiency, increases the substrate conversion rate, under a material concentration of 3.5 mol / L, the 2,6-difluorobentrinile conversion rate is as high as 100%, the 2,6-difluorobenamide selectivity is 100%, and no by product 2,6- difluorobenzoic acid is generated. The separation and purification technology of target product is simplified, and the method has the advantages of mild reaction conditions, low requirements on equipment, and easy application to production.
Owner:TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY

Immobilized recombinant penicillin G acylase and application thereof

The invention discloses an immobilized recombinant penicillin G acylase and an application thereof to preparation of (S)-2-aryl-amino acid and cephalosporin antibiotics. The immobilized recombinant penicillin G acylase disclosed by the invention is capable of converting an S-type substrate into an S-type product within shorter time, high in substrate tolerance and strict in S selectivity for the substrate and structural analogues thereof; due to the addition of cobalt ions as well as a protective agent with phenylacetic acid and glycerin as enzyme active centers, the immobilized recombinant penicillin G acylase disclosed by the invention is prevented from being successfully subjected to multipoint covalent immobilization on the surface of an epoxy resin carrier under the condition that enzyme molecules are seriously inactivated in an immobilization process, and the immobilization method is simple and feasible, cheap in raw materials and suitable for large-scale operation; the immobilized recombinant penicillin G acylase can be used for synthesizing cephalosporin antibiotics and splitting the prepared (S)-2-aryl-amino acid, and can be continuously used for more than 50 batches before the activity of the immobilized enzyme is not remarkably reduced.
Owner:ZHEJIANG UNIV OF TECH

Recombinant R-Omega-transaminase, mutant and application of recombinant R-Omega-transaminase and mutant in asymmetrically synthesizing sitagliptin

The invention relates to application of novel recombinant R-Omega-transaminase and a high-activity mutant of the recombinant R-Omega-transaminase in asymmetrically synthesizing sitagliptin by catalyzing sitagliptin precursor ketone. The amino acid sequence of the recombinant R-Omega-transaminase is shown by SEQ ID:1, and the mutant of the recombinant R-Omega-transaminase is obtained by performingsingle-site mutation or multisite mutation on one or more of a 60th site, 113th site, 178th site, 233th site, 146th site, 214th site and 186th site of the amino acid sequence shown by SEQ ID:1. The mutant of the novel R-Omega-transaminase with high activity and high stereoselectivity is provided; the mutant has milestone significance in realizing autonomization and localization of a biological catalysis preparation technology for the sitagliptin; and the technology monopoly situation that an enzyme source is single in the process of asymmetrically synthesizing the sitagliptin at present can bechanged.
Owner:ZHEJIANG UNIV OF TECH

Lactamase, application of lactamase and method for preparing (1R,4S)-gamma-lactam through enzymatic resolution

The invention discloses lactamase, an application of the lactamase and a method for preparing (1R,4S)-gamma-lactam through enzymatic resolution. An amino acid sequence of the lactamase is as shown inSEQ ID NO.1. A nucleotide sequence of a nucleic acid molecule for encoding the lactamase is as shown in SEQ ID NO. 2. The method for preparing the (1R,4S)-gamma-lactam through enzymatic resolution comprises the following step of in a buffer solution system, mixing a substrate and the lactamase to react, wherein the substrate is 2-azabicyclo[2.2.1]hept-5-ene-3-one. The lactamase has the characteristics of high substrate tolerance and high activity, and when the lactamase is applied to the method for preparing the (1R,4S)-gamma-lactam through enzymatic resolution, the substrate with relatively high concentration can fully react under the action of the lactamase to obtain the (1R,4S)-gamma-lactam with relatively high yield and chiral purity, so that the production efficiency is improved, andthe production cost is reduced.
Owner:安徽红杉生物医药科技有限公司

Method for preparing cycloastragenol by double-enzyme compounding conversion of astragaloside

The invention relates to the technical field of biotransformation, in particular to a method for preparing cycloastragenol through double-enzyme compounding transformation of astragaloside. Accordingto the method, the astragaloside is used as a substrate, xylosidase and glucosidase are subjected to double-enzyme compounding, then xyloside bonds at the C3 position of the substrate and glucoside bonds at the C6 position of the substrate are broken through one-step hydrolysis, and the cycloastragenol is obtained. The purity of the obtained cycloastragenol can reach 98% or above, and the method is easy to operate, free of pollution, milder in reaction temperature, clear in enzyme conversion mechanism, and wider in enzyme substrate adaptability and is suitable for industrial production.
Owner:WEIHAI BAIHE BIOTECH +1

Method for preparing magnetic nano carrier immobilized aldolase with high substrate tolerance

The invention discloses a method for preparing magnetic nano carrier immobilized aldolase with high substrate tolerance. The method comprises the following steps of: 1) preparing super-paramagnetic Fe3O4 nano particles by co-precipitation of a mixture of ferrous and ferric iron salts, modifying the particles by using a silane coupling agent, and activating the outer surfaces of the modified particles by using glutaraldehyde to obtain surface activated magnetic nano particles; 2) stirring a purified and desalted aldolase buffer solution and a magnetic carrier at a low temperature, washing, performing freeze drying, and thus obtaining the magnetic nano carrier immobilized aldolase; and 3) catalyzing 2-deoxy-D-ribose-5-phosphoric acid by using the magnetic nano carrier immobilized aldolase as a catalyst to obtain 3-glyceraldehyde phosphate and acetaldehyde. In the reaction of catalyzing the 2-deoxy-D-ribose-5-phosphoric acid by using the immobilized aldolase, the tolerance of the acetaldehyde substrate is remarkably improved, and the recycling operation of enzyme is greatly simplified.
Owner:ZHEJIANG UNIV

Tyrosinase mutant and application thereof

The invention belongs to the technical field of enzyme engineering, and relates to a tyrosinase mutant and application thereof. According to the tyrosinase mutant, a plurality of amino acid sites are mutated in wild type tyrosinase with an amino acid sequence as shown in SEQ ID NO.1. According to the tyrosinase mutant and the method for preparing theaflavin by using the tyrosinase mutant, the mutant has higher specific activity than wild type tyrosinase, and has higher yield during catalytic preparation of theaflavin.
Owner:HUNAN FLAG BIOTECHNOLOGY CO LTD +1

Multicellular system for regulating products by changing ventilating condition and fermenting method

The invention discloses a multicellular system for regulating products by changing the ventilating condition and a fermenting method. The multicellular system comprises anaerobic clostridium strains,facultative klebsiella pneumonia strains and escherich's bacillus strains, the total number of effective living bacteria is 97 percent or above that in the multicellular system, wherein the ratio of effective living bacteria of the anaerobic clostridium strains, facultative klebsiella pneumonia strains and escherich's bacillus strains is (60-90):(5-40):(1-10). The multicellular system has stable fermenting performance and strong tolerance under micro-aerobic / anaerobic condition, and can be used for efficiently transforming crude glycerine into 1,3-propylene glycol, lactic acid and butyric acid, different multicellular factories can be constructed from cell sizes by flexible combination of different cells of microorganisms, and the material flow and energy flow of cellular metabolism of microorganisms can be re-distributed by manually controlled recombination and optimization, so that platform compounds can be efficiently prepared.
Owner:DALIAN UNIV OF TECH

Acylase for producing 7-ACA (Aminocephalosporanic acid) by splitting CPC (Cephalosporin C) by utilizing a one-step method and polynucleotide encoding same

The invention discloses an acylase for producing 7-ACA (Aminocephalosporanic acid) by splitting CPC (Cephalosporin C) by utilizing a one-step method, polynucleotide encoding the same, a recombinant expression vector containing a nucleotide sequence, a recombinant expression transformant containing the nucleotide sequence, a preparation method of the acylase and an application of a recombinase in synthesis of the 7-ACA. A CPC acylase is a protein of (a) or (b) as follows: (a) a protein which has CPC acylase activity and an amino acid sequence represented by SEQ ID NO.3, wherein 180-site valine is substituted; and (b) a protein which has the CPC acylase activity and an amino acid sequence formed by adding one or multiple amino acids to an N terminal or a C terminal of the amino acid sequence in the (a) and is derivative from (a). According to the CPC acylase disclosed by the invention, both the enzyme activity and the substrate tolerance are improved, so that a strong precondition is provided for manual determinated evolution transformation of the CPC acylase.
Owner:SHANGHAI INST OF PHARMA IND +1

Application of oxidoreductase and mutant thereof in biosynthesis of noottanone

ActiveCN114480512AGood substrate toleranceGood effectFungiMicroorganism based processesKiller yeastSite-directed mutagenesis
The invention discloses an application of oxidoreductase and a mutant thereof in biosynthesis of noottanone, and belongs to the technical field of bioengineering. According to the present invention, the oxidation-reduction enzyme having high nodulariol conversion ability is obtained from the marine killer yeast (Wickhamomyces anomalusM15) for the first time, and the oxidation-reduction enzyme mutant having high ability is obtained through site-specific mutagenesis; compared with the existing oxidoreductase capable of catalyzing nodulariol, the oxidoreductase and the mutant thereof have good substrate tolerance, high conversion rate and high salt tolerance. According to the oxidoreductase and the mutant thereof provided by the invention, conditions are provided for synthesizing noottanone in an in-vitro enzyme catalysis manner, and noottanone products are synthesized by catalyzing noottanol in a green and efficient manner. According to the invention, an important tool enzyme is provided for the synthesis of noottanone, and huge economic benefits are brought to the synthesis industry of noottanone.
Owner:SOUTH CHINA UNIV OF TECH

A method for preparing 2,6-difluorobenzamide by using Rhodococcus rubrum

The invention relates to a preparation method of 2,6-difluorobenzamide by utilizing rhodococcus ruber. The method comprises the following steps: (1) fermentation and culture of seeds; (2) preparation of rhodococcus ruber suspension fluid; (3) conversion of 2,6-difluorobenzonitrile; (4) preparation of finished products. The invention provides a preparation method of 2,6-difluorobenzamide by utilizing rhodococcus ruber to convert 2,6-difluorobenzonitrile into 2,6-difluorobenzamide. The microorganism conversion method has a very high catalytic efficiency, increases the substrate conversion rate, under a material concentration of 3.5 mol / L, the 2,6-difluorobentrinile conversion rate is as high as 100%, the 2,6-difluorobenamide selectivity is 100%, and no by product 2,6- difluorobenzoic acid is generated. The separation and purification technology of target product is simplified, and the method has the advantages of mild reaction conditions, low requirements on equipment, and easy application to production.
Owner:TIANJIN UNIV OF SCI & TECH

Preparation method of chitosan microspheres for cell immobilization and drug delivery

The invention discloses a preparation method of chitosan microspheres for cell immobilization and drug delivery, and relates to the field of preparation of chitosan microspheres. According to the method, chitin is deacetylated by combining a compound enzyme with a microwave induction process technology, the chitosan is subjected to heavy metal green chelation by adopting tetrasodium glutamate diacetate or citric acid, and the extraction and removal capabilities of a chelating agent on residual metal ions are further improved by further utilizing a carbonate dissolution promoting technology; and trace proteins and lipids in crude chitosan products are hydrolyzed and separated by selecting a proper biological enzyme, refined chitosan is obtained, enzymatic molecular modification is performed on the refined chitosan by using transglycosides or oxidase, and finally the chitosan microspheres are prepared by using a green and environment-friendly spray drying method. The prepared chitosan microspheres are smooth in shape and uniform in size, the particle size is 1-250 microns, the chitosan microspheres are of a core-shell structure, and the application range of chitosan in the fields of medicine, food and other industries is widened by utilizing chitosan immobilized enzyme.
Owner:上海信卓实业有限公司

An acylase that cleaves cpc to produce 7-aca in one step and its polynucleotide

The invention discloses an acylase for producing 7-ACA (Aminocephalosporanic acid) by splitting CPC (Cephalosporin C) by utilizing a one-step method, polynucleotide encoding the same, a recombinant expression vector containing a nucleotide sequence, a recombinant expression transformant containing the nucleotide sequence, a preparation method of the acylase and an application of a recombinase in synthesis of the 7-ACA. A CPC acylase is a protein of (a) or (b) as follows: (a) a protein which has CPC acylase activity and an amino acid sequence represented by SEQ ID NO.3, wherein 180-site valine is substituted; and (b) a protein which has the CPC acylase activity and an amino acid sequence formed by adding one or multiple amino acids to an N terminal or a C terminal of the amino acid sequence in the (a) and is derivative from (a). According to the CPC acylase disclosed by the invention, both the enzyme activity and the substrate tolerance are improved, so that a strong precondition is provided for manual determinated evolution transformation of the CPC acylase.
Owner:SHANGHAI INST OF PHARMA IND CO LTD +1

Recombinant r-ω-transaminase, mutant and its application in asymmetric synthesis of sitagliptin

The invention relates to the application of a novel recombinant R-ω-transaminase and its high-activity mutant in catalyzing the asymmetric synthesis of sitagliptin precursor ketone. The amino acid sequence of the recombinant R-ω-transaminase is shown in SEQ ID: 1, and its mutant is the 60th, 113, 178, 233, 146, 214 or 186 of the amino acid sequence shown in SEQ ID: 1 One or more single-site mutations or multi-site mutations are obtained. The present invention provides a novel R-omega-TA mutant with high activity and high stereoselectivity, which is a milestone in realizing the self-management and localization of sitagliptin biocatalytic preparation technology, and can change the current asymmetric synthesis of sitagliptin The technical monopoly situation of a single enzyme source in the process of Gliptin.
Owner:ZHEJIANG UNIV OF TECH

A carbonyl reductase mutant mut-accr(i147v/g152l) and its application and coding gene

The invention provides a carbonyl reductase mutant mut-AcCR (I147V / G152L) and its application and coding gene. Carbonyl reductase AcCR can catalyze the asymmetric reduction of various latent chiral carbonyl compounds, but its activity and substrate tolerance to aromatic compounds are low. The present invention adopts enzyme molecular transformation method to mutate glycosylation reductase AcCR , the mutant mut‑AcCR (I147V / G152L) was obtained. The specific enzyme activity of the mutant for 2‑hydroxyacetophenone can reach 6.4 U / mg, which is 17.4 times higher than that of the unmutated carbonyl reductase. The substrate tolerance concentration was increased from 50 mmol / L to 200 mmol / L. The carbonyl reductase mutants of the present invention are widely used in the asymmetric reduction of carbonyl compounds.
Owner:SOUTH CHINA UNIV OF TECH

A method for preparing cycloastragaloside by compound transformation of astragaloside IV with double enzymes

The invention relates to the technical field of biotransformation, in particular to a method for preparing cycloastragalol by compound transformation of astragaloside IV with double enzymes. The method of the present invention takes astragaloside IV as a substrate, utilizes xylosidase and glucosidase double-enzyme complex, and then undergoes one-step hydrolysis to cleave the substrate C. 3 position of the xylosidic bond and C 6 The method for obtaining cycloastragalus by the position of the glucosidic bond. The purity of cycloastragalol obtained by the invention can reach more than 98%, and the method has simple operation, no pollution, milder reaction temperature, clear enzymatic transformation mechanism and wider enzyme substrate adaptability, and is suitable for industrial production.
Owner:WEIHAI BAIHE BIOTECH +1

AMA synthetase and application thereof in synthesis of AMA or derivatives thereof

ActiveCN110982796AHigh atom economy and environmental friendlinessGood substrate toleranceEnzymesFermentationGenetic engineeringPhosphoserine
The invention provides an AMA synthetase and its application in synthesis of AMA or its derivatives, and belongs to the technical field of genetic engineering. The gene sequence of the AMA synthetaseis shown as SEQ ID No. 2, and the encoded protein sequence is shown as SEQ ID No. 1. It is found that the AMA synthetase derived from fungi can effectively make O-acetylserine or O-phosphoserine usedas a substrate react with natural amino acids to generate Toxin A or derivatives thereof and further catalyze Toxin A or derivatives thereof to generate AMA and / or any one of AMA derivatives. The AMAsynthetase provided by the invention has broad application prospects in the field of antibiotic adjuvant preparation.
Owner:PEKING UNIV

A kind of AMA synthetase and its application in synthesizing AMA or its derivatives

The invention provides an AMA synthetase and its application in synthesizing AMA or its derivatives, belonging to the technical field of genetic engineering. The AMA synthetase gene sequence of the present invention is shown in SEQ ID No.2, and its encoded protein sequence is shown in SEQ ID No.1. The present invention finds that the AMA synthetase derived from fungi can react O-acetylserine or O-phosphoserine as a substrate with natural amino acids at low cost and efficiently to generate Toxin A or its derivatives and further catalyze Toxin A or its derivatives Any of AMA and / or AMA derivatives are produced. The AMA synthetase provided by the invention has broad application prospects in the field of antibiotic adjuvant preparation.
Owner:PEKING UNIV

Recombinant carbonyl reductase mutant, gene, vector, engineering bacteria and application thereof

The invention discloses a recombinant carbonyl reductase mutant, a gene, a vector, an engineering bacterium and application of the recombinant carbonyl reductase mutant. The mutant is obtained by performing single-point mutation on the 95th locus, the 144th locus or the 156th locus of an amino acid sequence shown as SEQ ID NO.2. The recombinant carbonyl reductase mutant has reduced (S)-6-chloro-5-hydroxy-3-oxohexanoate, and compared with a wild type enzyme, has the advantages that the catalytic activity and the substrate tolerance are greatly improved when such reaction is converted, and the time consumption of a reaction process is obviously reduced. Compared with a chemical method for preparing (3R,5S)-6-chloro-3,5-dihydroxyhexanoate, such a technology has the advantages that an obtained product is high in stereoselectivity, a tedious chemical catalysis step is simplified, the reaction condition is milder, the requirement on equipment is low, the reaction cost is reduced, and the technology is environment-friendly.
Owner:ZHEJIANG UNIV OF TECH

(r)-ω-transaminase mutant and its application in the preparation of sitagliptin intermediate

The present invention discloses a (R)-ω-transaminase mutant and its application in the preparation of sitagliptin intermediate, the mutant consists of arginine at position 77 of the amino acid sequence shown in SEQ ID NO.1 , leucine at position 181, arginine at position 130, tyrosine at position 139 and threonine at position 273 were obtained by multiple point mutations. The present invention screens novel (R)‑ω‑TA recombinases through gene mining technology, and carries out molecular transformation through protein engineering technology to obtain (R)‑ω‑TA recombinase with high enzyme activity, high substrate tolerance and high stereoselectivity. Omega-TA mutant catalyst, this mutant can be precursor ketone analogue 1-(pyrrolidin-1-yl)-4-(2,4,5-trifluorophenyl)-1,3-butanedione as Synthesis of sitagliptin intermediate (R)-3-amino-1-(pyrrolidin-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one by substrate asymmetric catalysis , and the conversion rate is high, up to 94.6%.
Owner:ZHEJIANG UNIV OF TECH +2

Application of bacillus DL-1 whole cell in catalytic resolution of styralyl acetate

The present invention discloses an application of a bacillus DL-1 whole cell in catalytic resolution of styralyl acetate. The bacillus DL-1 whole cell can be used as a catalyst to prepare chiral (R)-1-phenylethanol and (S)-styralyl acetate with high optical purity. Under optimal reaction conditions, an enantiomeric excess value of the (R)-1-phenylethanol obtained by the bacillus DL-1 whole cell catalytic resolution of (+ or -)-styralyl acetate is 96.6%, a conversion rate is 24.5% and yield is 48.1%; the enantiomeric excess value of the obtained (S)-styralyl acetate by the catalytic resolutionof the (+ or -)-styralyl acetate is 98.4%, the conversion rate is 56.6% and the yield is 86.2%. The bacillus DL-1 whole cell as the biocatalyst has relatively high substrate tolerance and optical selectivity in the chiral resolution of the (+ or -)-styralyl acetate, and has relatively great application value in the field of biochemical engineering.
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY - CHINESE ACAD OF SCI

Recombinant r-type transaminase, mutant and application thereof

The invention relates to a recombinant R-ω-transaminase and a mutant, as well as its application in the asymmetric synthesis of sitagliptin. The present invention screens novel R-ω-transaminase, and recombines with existing high-efficiency transaminase, the amino acid sequence of the obtained recombinant is shown in SEQ ID: 15, and its mutant is the amino acid sequence shown in SEQ ID: 15. One or more of 71, 135, or 292 obtained by single point mutation or multi-site mutation, the amino acid sequence of the best R-ω-transaminase mutant strain is shown in SEQ ID: 17, the corresponding nucleotide The sequence is shown as SEQ ID:18. The present invention provides R-ω-TA mutants with higher activity (582.4U / g) and stereoselectivity (e.e. value 99.9%), which can catalyze the conversion of 500mM substrate into sitagliptin, and the conversion rate is as high as 99% , which is of great significance for improving the biocatalytic preparation technology of sitagliptin.
Owner:ZHEJIANG UNIV OF TECH

A carbonyl reductase mutant mut-accr(g152l/y189n) and its application and coding gene

The invention discloses a carbonyl reductase mutant mut-AcCR (G152L / Y189N) and its application and coding gene. Carbonyl reductase AcCR can catalyze the asymmetric reduction of various latent chiral carbonyl compounds, but its activity and substrate tolerance to aromatic compounds are low. The present invention adopts enzyme molecular transformation method to mutate glycosylation reductase AcCR , to obtain the mutant mut-AcCR (G152L / Y189N), the specific enzyme activity of the mutant for 2-oxo-4-phenylbutyrate ethyl ester can reach 88.9U / mg, which is higher than that of the carbonyl reductase before the mutation The specific vitality is increased by 61.3 times. The substrate tolerance concentration was increased from 50mmol / L to 200mmol / L. The mutant catalyzed ethyl 2‑oxo‑4‑phenyl‑butyrate with absolute selectivity, and the enantiomeric excess value of the product increased from 82.9% to >99%. The carbonyl reductase mutant of the present invention plays an important role in catalyzing the asymmetric reduction of ethyl 2-oxo-4-phenylbutyrate.
Owner:SOUTH CHINA UNIV OF TECH

A kind of (r)-omega-transaminase mutant and its application

The present invention discloses a mutant of (R)-ω-transaminase and its application. The mutant is composed of leucine at position 182, arginine at position 79, arginine at position 51 in the amino acid sequence shown in SEQ ID NO.1. Glutamine at position 1, valine at position 149, leucine at position 235 and glycine at position 216 were obtained through multiple point mutations. The present invention screens novel (R)-ω-TA enzymes through gene mining technology, and carries out molecular transformation through protein engineering technology to obtain (R)-ω-TA enzymes with high enzyme activity, high substrate tolerance and high stereoselectivity ‑TA mutant catalyst capable of biocatalyzing the precursor ketone analog 1‑(3‑oxypyrrolidin‑1‑yl)‑4‑(2,4,5‑trifluorophenyl)‑1,3‑ Synthesis of sitagliptin intermediate (R)-1-[3-amino-4-(2,4,5-trifluorophenyl) butyryl]pyrrole-3-one from diacetyl, with high conversion rate, It can reach up to 95.4%, which is a milestone for breaking through the biocatalytic preparation technology of sitagliptin.
Owner:ZHEJIANG UNIV OF TECH +2

Lactamase and its application and method for enzymatic resolution and preparation of (1r, 4s)-venslide

The invention discloses a lactamase, its application and a method for enzymatic resolution and preparation of (1R, 4S)-vins lactone. The amino acid sequence of the lactamase is shown in SEQ ID NO.1. The nucleotide sequence of the nucleic acid molecule encoding the above-mentioned lactamase is shown in SEQ ID NO.2. The method for enzymatic resolution and preparation of (1R, 4S)-wens lactone comprises: in a buffer system, the substrate and the above-mentioned lactamase are mixed and reacted, and the substrate is 2-azabicyclo[2.2.1]heptane ‑5‑en‑3‑one. The lactamase has the characteristics of high substrate tolerance and high activity, and it is used in the method of enzymatic resolution and preparation of (1R, 4S)-Wens lactone, which can make a higher concentration of the substrate Fully reacting under the action of the lactamase, the (1R, 4S)-wens lactone with higher yield and chiral purity is obtained, which improves production efficiency and reduces production cost.
Owner:安徽红杉生物医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products